ClinicalTrials.gg
CompletedNCT02913326Updated Aug 15, 2019Results posted

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

A Phase 3 interventional study of Dabigatran etexilate and Warfarin in Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 36 sites in 9 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2019-08-15.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Thromboembolism by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Thromboembolism · Boehringer Ingelheim.

Started
2016
the only one that year
Phase 3
7 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Thromboembolism by Boehringer Ingelheim, this one is the only one that started in 2016, is one of 7 in phase 3, and was the 11th registered.

Thromboembolism

288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.

Browse Thromboembolism studies →

Open to participants now

None of the 12 studies in Thromboembolism by Boehringer Ingelheim is open now. The open studies under Thromboembolism, anywhere →

Who these studies take

Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Thromboembolism by Boehringer Ingelheim as a file.
02

Study summary

This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted warfarin on a net clinical benefit endpoint of major bleeding (ISTH criteria) and new venous thrombotic event (VTE) (primary endpoint) with blinded endpoint adjudication.

03

Conditions studied

  • Thromboembolism

Browse trials for

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written in accordance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and local legislation and/or regulations
  • Confirmed diagnosis of Cerebral Venous or dural sinus thrombosis (CVT), with or without intracranial haemorrhage
  • Completion of anticoagulation therapy for 5-15 days which has been administered until randomisation; anticoagulation must include full-dose low molecular weight heparin or unfractionated heparin
  • Eligibility for treatment with an oral anticoagulant
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Cerebral Venous or dural sinus thrombosis (CVT) associated with central nervous system infection or due to head trauma
  • Planned surgical treatment for CVT
  • Conditions associated with increased risk of bleeding
  • History of symptomatic non-traumatic intracranial haemorrhage with risk of recurrence according to Investigator judgment
  • Treatment with an antithrombotic regimen for an indication other than CVT and requiring continuation of that treatment for the original diagnosis without change in the regimen
  • Severe renal impairment
  • Active liver disease
  • Pregnancy, nursing or planning to become pregnant while in the trial
  • Further exclusion criteria apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Dabigatran etexilate

    Drug: Dabigatran etexilate

  • Active comparator
    Warfarin

    Drug: Warfarin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period.

    Composite of the percentage of participants with MBE according to ISTH criteria and VTE (recurring cerebral venous thrombosis (CVT); deep venous thrombosis (DVT) of any limb, pulmonary embolism (PE), splanchnic vein thrombosis) in full observation period. All components were adjudicated in a blinded manner. Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed

    Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.

Secondary outcomes

  1. Percentage of Participants With Recurring Cerebral Venous and Dural Sinus Thrombosis; DVT of Any Limb, PE or Splanchnic Vein Thrombosis in Full Observation Period

    VTE criterions: * New neurological signs/symptoms or worsening of previous signs/symptoms with new CVT on neuroimaging. * DVT of any limb was documented by: Abnormal compression ultrasonography; An intraluminal filling defect on venography; At autopsy * Splanchnic vein thrombosis: The presence of endoluminal material/absence of flow in the extrahepatic portal veins/mesenteric veins as shown by duplex-Doppler ultrasound/contrast-enhanced CT scan/MRI. * PE was documented by: An intraluminal filling defect in segmental/more proximal branches on spiral CT scan; An intraluminal filling defect/an extension of an existing defect/a sudden cut-off of vessels\>2.5 mm in diameter on the pulmonary angiogram; Perfusion defect of at least 75% of a segment with a local normal ventilation result on ventilation/perfusion lung scan; Inconclusive spiral CT, pulmonary angiography/lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasonography/venography; At autopsy.

    Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.

  2. Cerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24

    Cerebral venous recanalisation was assessed by imaging and was adjudicated. Occlusion of cerebral veins and sinuses was scored as: 1 = full occlusion; 0 = no occlusion/partial occlusion. This score was applied using the below conventions: Superior sagittal, straight, cavernous sinuses, left and right jugular veins each scored individually as either 0 or 1; Right lateral transverse and sigmoid sinus were scored together, Left lateral transverse and sigmoid sinus were scored together, Superior petrous sinus and inferior petrous sinus were scored together; Deep venous system, Superficial cortical veins, Cerebellar veins were scored as systems. For each patient a total score was calculated at baseline and at EOT and the recanalisation score was calculated as EOT - baseline total scores with conventions as 0 = no cerebral veins or sinuses fully occluded and 11 = all cerebral veins and sinuses fully occluded; the lower the score, the better.

    Time frame: Baseline and week 24

  3. Percentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period

    Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed

    Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.

  4. Composite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks

    Intracranial haemorrhage (ICH) comprised the subtypes of intracerebral bleeds, subdural bleeds, epidural bleeds and subarachnoid bleeds that were recorded.

    Time frame: From first administration of trial medication until end of treatment visit, up to 24 weeks.

  5. Percentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period.

    A clinically relevant non-major bleeding event (CRNMBE) was a clinically overt bleed that did not meet the criteria for a major bleed but prompted a clinical response, in that it led to at least 1 of the following: A hospital admission (i.e. overnight stay in the hospital) for bleeding / A physician guided medical or surgical treatment for bleeding / A physician guided change, interruption or discontinuation of trial medication.

    Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.

  6. Percentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks

    Percentage of participants with major bleeding according to ISTH criteria or CRNMBEs after up to 24 weeks.

    Time frame: From first administration of trial medication until end of treatment visit, up to 24 weeks.

  7. Percentage of Participants With Any Bleeding Event After up to 24 Weeks

    Percentage of participants with any bleeding event after up to 24 weeks where any bleeding event is the sum of all major and non-major bleeding events.

    Time frame: From first administration of trial medication until end of treatment visit, up to 24 weeks.

07

Results

Posted Aug 15, 2019

Participant flow

This is a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE \[prospective, randomised, open-label, blinded endpoint\] design), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with cerebral venous and dural sinus thrombosis over a 24-week period.

Participant flow — Overall Study
MilestoneDabigatran EtexilateWarfarin
Started6060
Completed5958
Not completed12
Withdrew: Reason not listed01
Withdrew: Lost to follow-up01
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period.

Composite of the percentage of participants with MBE according to ISTH criteria and VTE (recurring cerebral venous thrombosis (CVT); deep venous thrombosis (DVT) of any limb, pulmonary embolism (PE), splanchnic vein thrombosis) in full observation period. All components were adjudicated in a blinded manner. Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed

Time frame:
From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period.
Percentage of participantsDabigatran EtexilateWarfarin
Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period.1.7 (0.0 to 8.9)3.3 (0.4 to 11.5)
SecondaryPercentage of Participants With Recurring Cerebral Venous and Dural Sinus Thrombosis; DVT of Any Limb, PE or Splanchnic Vein Thrombosis in Full Observation Period

VTE criterions: * New neurological signs/symptoms or worsening of previous signs/symptoms with new CVT on neuroimaging. * DVT of any limb was documented by: Abnormal compression ultrasonography; An intraluminal filling defect on venography; At autopsy * Splanchnic vein thrombosis: The presence of endoluminal material/absence of flow in the extrahepatic portal veins/mesenteric veins as shown by duplex-Doppler ultrasound/contrast-enhanced CT scan/MRI. * PE was documented by: An intraluminal filling defect in segmental/more proximal branches on spiral CT scan; An intraluminal filling defect/an extension of an existing defect/a sudden cut-off of vessels\>2.5 mm in diameter on the pulmonary angiogram; Perfusion defect of at least 75% of a segment with a local normal ventilation result on ventilation/perfusion lung scan; Inconclusive spiral CT, pulmonary angiography/lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasonography/venography; At autopsy.

Time frame:
From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Reported as:
Number · Percentage of participants
Percentage of Participants With Recurring Cerebral Venous and Dural Sinus Thrombosis; DVT of Any Limb, PE or Splanchnic Vein Thrombosis in Full Observation Period
Percentage of participantsDabigatran EtexilateWarfarin
Recurring CVT0.0 (0.0 to 6.0)0.0 (0.0 to 6.0)
DVT of any limb0.0 (0.0 to 6.0)0.0 (0.0 to 6.0)
PE0.0 (0.0 to 6.0)0.0 (0.0 to 6.0)
Splanchnic vein thrombosis0.0 (0.0 to 6.0)0.0 (0.0 to 6.0)
SecondaryCerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24

Cerebral venous recanalisation was assessed by imaging and was adjudicated. Occlusion of cerebral veins and sinuses was scored as: 1 = full occlusion; 0 = no occlusion/partial occlusion. This score was applied using the below conventions: Superior sagittal, straight, cavernous sinuses, left and right jugular veins each scored individually as either 0 or 1; Right lateral transverse and sigmoid sinus were scored together, Left lateral transverse and sigmoid sinus were scored together, Superior petrous sinus and inferior petrous sinus were scored together; Deep venous system, Superficial cortical veins, Cerebellar veins were scored as systems. For each patient a total score was calculated at baseline and at EOT and the recanalisation score was calculated as EOT - baseline total scores with conventions as 0 = no cerebral veins or sinuses fully occluded and 11 = all cerebral veins and sinuses fully occluded; the lower the score, the better.

Time frame:
Baseline and week 24
Reported as:
Mean · Units on scale
Cerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24
Units on scaleDabigatran EtexilateWarfarin
Cerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24-0.8 ± 0.78-1.0 ± 0.92
SecondaryPercentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period

Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed

Time frame:
From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period
Percentage of participantsDabigatran EtexilateWarfarin
Percentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period1.7 (0.0 to 8.9)3.3 (0.4 to 11.5)
SecondaryComposite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks

Intracranial haemorrhage (ICH) comprised the subtypes of intracerebral bleeds, subdural bleeds, epidural bleeds and subarachnoid bleeds that were recorded.

Time frame:
From first administration of trial medication until end of treatment visit, up to 24 weeks.
Reported as:
Number · Percentage of participants
Composite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks
Percentage of participantsDabigatran EtexilateWarfarin
Composite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks1.8 (0.0 to 9.6)3.8 (0.5 to 13.0)
SecondaryPercentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period.

A clinically relevant non-major bleeding event (CRNMBE) was a clinically overt bleed that did not meet the criteria for a major bleed but prompted a clinical response, in that it led to at least 1 of the following: A hospital admission (i.e. overnight stay in the hospital) for bleeding / A physician guided medical or surgical treatment for bleeding / A physician guided change, interruption or discontinuation of trial medication.

Time frame:
From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period.
Percentage of participantsDabigatran EtexilateWarfarin
Percentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period.0.0 (0.0 to 6.0)1.7 (0.0 to 8.9)
SecondaryPercentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks

Percentage of participants with major bleeding according to ISTH criteria or CRNMBEs after up to 24 weeks.

Time frame:
From first administration of trial medication until end of treatment visit, up to 24 weeks.
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks
Percentage of participantsDabigatran EtexilateWarfarin
Percentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks1.7 (0.0 to 8.9)5.0 (1.0 to 13.9)
SecondaryPercentage of Participants With Any Bleeding Event After up to 24 Weeks

Percentage of participants with any bleeding event after up to 24 weeks where any bleeding event is the sum of all major and non-major bleeding events.

Time frame:
From first administration of trial medication until end of treatment visit, up to 24 weeks.
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Bleeding Event After up to 24 Weeks
Percentage of participantsDabigatran EtexilateWarfarin
Percentage of Participants With Any Bleeding Event After up to 24 Weeks20.0 (10.8 to 32.3)20.0 (10.8 to 32.3)

Adverse events

Collected over From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate0/60 (0%)8/60 (13.3%)21/60 (35%)
Warfarin0/60 (0%)6/60 (10%)17/60 (28.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventDabigatran EtexilateWarfarin
Subdural haematomaInjury, poisoning and procedural complications0/602/60
PyelonephritisInfections and infestations0/601/60
Severe fever with thrombocytopenia syndromeInfections and infestations0/601/60
Urinary tract infectionInfections and infestations0/601/60
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/600/60
Evans syndromeBlood and lymphatic system disorders1/600/60
Cerebral haemorrhageNervous system disorders1/600/60
Cerebral infarctionNervous system disorders1/600/60
EpilepsyNervous system disorders1/600/60
Intracranial aneurysmNervous system disorders1/600/60
Most frequent other events
Most frequent other events
EventDabigatran EtexilateWarfarin
HeadacheNervous system disorders10/608/60
CoughRespiratory, thoracic and mediastinal disorders5/600/60
DiarrhoeaGastrointestinal disorders4/602/60
DyspepsiaGastrointestinal disorders4/600/60
DepressionPsychiatric disorders2/604/60
InsomniaPsychiatric disorders0/604/60

Baseline characteristics

Treated set (TS): The set includes patients who received at least one dose of study medication and were analysed according to the treatment they received.

Age, Continuous
Age, Continuous(Years)Dabigatran EtexilateWarfarinTotal
Mean44.4 ± 14.0646.0 ± 13.6445.2 ± 13.82
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran EtexilateWarfarinTotal
Female333366
Male272754
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran EtexilateWarfarinTotal
Hispanic or Latino41115
Not Hispanic or Latino524395
Unknown or Not Reported4610
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dabigatran EtexilateWarfarinTotal
American Indian or Alaska Native000
Asian12719
Native Hawaiian or Other Pacific Islander000
Black or African American000
White454994
More than one race000
Unknown or Not Reported347
08

Study locations

36 sites
  • HOP Pellegrin
    Bordeaux, 33076, France
  • HOP Lariboisière
    Paris, 75475, France
  • Vivantes Netzwerk für Gesundheit GmbH
    Berlin, 12351, Germany
  • Universitätsklinikum Essen AöR
    Essen, 45147, Germany
  • Asklepios Klinik Wandsbek
    Hamburg, 22043, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Mazumdar Shaw Medical centre
    Bangalore, 560099, India
  • Nizam's Institute of Medical Sciences
    Hyderabad, 500082, India
  • Caritas Hospital
    Kottayam, 686630, India
  • Magnum Heart Institute
    Nashik, 422005, India
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
  • Sahyadri Speciality Hospital
    Pune, 411004, India
  • ASST di Cremona
    Cremona, 26100, Italy
  • Fondazione Centro San Raffaele del Monte Tabor
    Milano, 20132, Italy
  • Nuovo Ospedale Civile S. Agostino-Estense
    Modena, 41126, Italy
  • A.O. San Camillo Forlanini
    Roma, 00152, Italy
  • Umberto I Pol. di Roma-Università di Roma La Sapienza
    Roma, 00161, Italy
  • A. O. Ospedale Circolo Fond. Macchi
    Varese, 21100, Italy
  • Academisch Medisch Centrum (AMC)
    Amsterdam, 1105 AZ, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • University Clinical Center, Gdansk
    Gdansk, 80211, Poland
  • Copernicus Med.Company.Ltd,Hosp.Nicolaus, Gdansk
    Gdansk, 80803, Poland
  • Independent Public Clin.Hospital No.4,Neurol.Dept,Lublin
    Lublin, 20-954, Poland
  • Psychiatry&Neurol.Instit.Interv.Stroke&Cerebrov.Treatm.Cntr
    Warsaw, 02-957, Poland
  • Hospital Fernando Fonseca, EPE
    Amadora, 2720-276, Portugal
  • CHLO, EPE - Hospital Egas Moniz
    Lisboa, 1349-019, Portugal
  • CHULN, EPE - Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Centro Hospitalar São João,EPE
    Porto, 4202-451, Portugal
  • Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião
    Santa Maria da Feira, 4520-211, Portugal
  • Reg.State Budget Hlthcare,City Hosp#5,Neurology Dept,Barnaul
    Barnaul, 656045, Russian Federation
  • Interreg. Clinical & Diagnostic Center, Neurol. Dept., Kazan
    Kazan, 420101, Russian Federation
  • St.Petersb,State Hlthcare Instit. Elisabeth Hosp,Neurol.dept
    Saint Petersburg, 195257, Russian Federation
  • Sverdlovsk Reg.Clin.Hosp.No.1
    Yekaterinburg, 620102, Russian Federation
  • Hospital Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital La Paz
    Madrid, 28046, Spain
09

References and documents

Publications

  • Ferro JM, Bendszus M, Jansen O, Coutinho JM, Dentali F, Kobayashi A, Aguiar de Sousa D, Neto LL, Miede C, Caria J, Huisman H, Diener HC; RE-SPECT CVT Study Group. Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. Int J Stroke. 2022 Feb;17(2):189-197. doi: 10.1177/17474930211006303. Epub 2021 Apr 4. PubMed 33724104 ↗
  • Ferro JM, Coutinho JM, Jansen O, Bendszus M, Dentali F, Kobayashi A, van der Veen B, Miede C, Caria J, Huisman H, Diener HC; RE-SPECT CVT Study Group. Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis. Stroke. 2020 Nov;51(11):3344-3347. doi: 10.1161/STROKEAHA.120.031235. Epub 2020 Sep 25. PubMed 32972315 ↗
  • Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhao P, Karpov D, Nagel S, Posthuma L, Roriz JM, Caria J, Frassdorf M, Huisman H, Reilly P, Diener HC; RE-SPECT CVT Study Group. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol. 2019 Dec 1;76(12):1457-1465. doi: 10.1001/jamaneurol.2019.2764. PubMed 31479105 ↗
  • Ferro JM, Dentali F, Coutinho JM, Kobayashi A, Caria J, Desch M, Fraessdorf M, Huisman H, Diener HC. Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis. Int J Stroke. 2018 Oct;13(7):766-770. doi: 10.1177/1747493018778125. Epub 2018 May 18. PubMed 29775170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Jun 2018, 18 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 23, 2016
StartActual
Dec 13, 2016
Primary completionActual
Jun 22, 2018
CompletionActual
Jun 22, 2018
Results first posted
Aug 15, 2019
Last update
Aug 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02913326
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Dec 13, 2016
Primary completion
Jun 22, 2018
Completion
Jun 22, 2018
Results posted
Aug 15, 2019
Last update
Aug 15, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion